Navigation Links
Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
Date:2/3/2009

NEW BRUNSWICK, N.J., Feb. 3 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) today announced results of efficacy, toxicological and dose-finding studies in mice for its potential multiple myeloma drug candidate, SNS-01. SNS-01 is a nano-encapsulated combination therapy of Factor5A and an siRNA against Factor 5A. These studies, undertaken to determine the efficacy, maximum tolerated dose and the feasibility of long-term intravenous administration of SNS-01, were performed at the University of Waterloo, Ontario, Canada.

The Company's anti-myeloma efficacy study in severe combined immune-deficient mice with human multiple myeloma subcutaneous tumors tested SNS-01 dosages ranging from 0.15 mg/kg to 1.5 mg/kg. In these studies, mice treated with a dose of either 0.75 mg/kg or 1.5 mg/kg both showed a 91% reduction in tumor volume and a decrease in tumor weight of 87% and 95%, respectively. For mice that received smaller doses of either 0.38 mg/kg or 0.15 mg/kg, there was also a reduction in tumor volume (73% and 61%, respectively) and weight (74% and 36%, respectively). All of the treated mice, regardless of dose, survived.

This therapeutic dose range provided the basis for an 8-day maximum tolerated dose study in which normal mice received two intravenous doses of increasing amounts of SNS-01 (from 2.2 mg/kg to 3.7 mg/kg). Body weight, organ weight and serum levels of liver enzymes were used as clinical indices to assess toxicity. A dose between 2.2 mg/kg and 2.9 mg/kg was well tolerated with respect to these clinical indices, and the survival rate at 2.9 mg/kg was 80%. Those mice receiving above 2.9 mg/kg of SNS-01 showed evidence of morbidity and up to 80% mortality. The 2.9 mg/kg threshold, twice the upper end of the therapeutic dose range, was therefore determined to be the maximum tolerated dose in mice.

The final study, a
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference
2. Senesco Expands on Preclinical Multiple Myeloma Findings
3. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
4. SmartNow.com Announces the Appointment of Dr. Melina Jampolis as Chief Medical Officer
5. Carriage Services Announces Fourth Quarter Earnings Release And Conference Call Schedule
6. Weight Watchers Announces Fourth Quarter and Full Year 2008 Earnings Conference Call
7. Hudsonville Ice Cream Announces Recall
8. American Dietetic Association Announces Agenda for Health Reform
9. Hologic Announces First Quarter Fiscal 2009 Operating Results
10. Arizona Heart Institute Announces FREE Public Forum Featuring Live Viewing of Surgical Procedures Via High-Definition (HD) Satellite
11. Aflac Incorporated Announces Fourth Quarter Results, Sees 2008 RBC Ratio Above 450%, Affirms 2009 Operating EPS Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 19, 2014 (HealthDay News) -- A group representing ... get a flu shot. According to the American ... in recent years have upheld the safety and effectiveness ... is highly infectious and can be particularly dangerous to ... and other complications," Dr. Laura Riley, chair of the ...
(Date:8/20/2014)... that the immune system is defective in people suffering from ... have ongoing issues with pain. , The research the ... help to explain why some painkillers may not offer satisfactory ... to 10% of the community. There are different forms ... which often has the greatest impact on sufferers, quality of ...
(Date:8/20/2014)... Barbara Bronson Gray HealthDay Reporter ... extremely rare, colds, flu and other minor infections might ... stroke in children, a new study suggests. Just five ... the United States, said Dr. Heather Fullerton, lead author of ... the University of California, San Francisco Benioff Children,s Hospital. "It ...
(Date:8/20/2014)... 2014 The Board of Directors of ... is pleased to announce the expansion of its ... China and the surrounding region. In support of ... AIA has relocated to the firm’s office in ... planning and design and to better support regional clients. ...
(Date:8/20/2014)... City, Utah (PRWEB) August 20, 2014 With ... 500’s 2014 list of the nation’s fastest growing companies. The ... in the health care sector. Connexion Point is the #1 ... contact centers in Medicare and Medicaid, and its clients include ... nation. Connexion Point employs 1,000 people and has offices and ...
Breaking Medicine News(10 mins):Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Pain treatments less effective for those with irritable bowel 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2
... Dr. Neil Kurtz Resigns as President and Chief Executive Officer; ... Graham Appointed Acting Chief Executive Officer -, LA ... ) today announced that Neil Kurtz, M.D., is,resigning as President, ... of August 31, 2008. Dr. Kurtz is leaving TorreyPines,to assume ...
... genetic variation , , FRIDAY, Aug. 8 (HealthDay News) -- A ... salt intake and high blood pressure. , The study, which ... possible genetic factor that might make people more or less ... -- variants of a gene for angiotensinogen, a molecule that ...
... polar opposite diseases, but both depend upon dopamine in ... drug addicts get too much of it. Although the ... known, the way it works has been a mystery. ... Medicine has revealed that dopamine strengthens and weakens the ...
... release is available in French . , ... that patients who receive early treatment for Hepatitis C ... develop a rapid poly-functional immune response against HCV similar ... new study published in the Journal of Virology ...
... Delayed diagnosis, less successful surgery, pair of studies finds , , ... for prostate cancer may not be accurate for obese men, ... less likely to be effective for them, a new pair ... be diagnosed with an aggressive form of the disease," said ...
... in Senior Housing Growing; Adoption of Healthy Lifestyle ... ... the face of conventional,wisdom, which has long proven true, women live longer ... than ever are moving,into senior living residences nationwide. Historically female-dominated,senior living communities ...
Cached Medicine News:Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 2Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 3Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 4Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 5Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 6Health News:TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results 7Health News:Too Much Salt Boosts Blood Pressure 2Health News:Why dopamine freezes parkinson patients and drives drug addicts 2Health News:Why dopamine freezes parkinson patients and drives drug addicts 3Health News:Early treatment is key to combating hepatitis C virus 2Health News:Obese Men Face Twin Threat From Prostate Cancer 2Health News:More Men Moving Into Senior Residences 2Health News:More Men Moving Into Senior Residences 3
(Date:8/20/2014)... MIRAGE, Calif. , Aug. 20, 2014 The ... named Fernando Davila has been successfully treated for ... disease", by Dr, Anibal R. Gauto , Medical Director ... Center, at Eisenhower Medical Center in Rancho Mirage, ... new treatment pioneered by Dr. John Crew at ...
(Date:8/20/2014)... -- Research and Markets  has announced the addition of ... their offering. Global Market Report of Pralmorelin ... and regionally ( Europe , Asia ... Latin America etc.). It captures Pralmorelin market trends, ... on three primary areas; manufacture methods & technology development, market ...
(Date:8/20/2014)... 20, 2014 Research and Markets ... "Global Advanced Wound Care and Closure Market (Types, ... Global Trends, Company Profiles, Demand, Insights, Analysis, Research, ... report to their offering. ... and closure market (types, applications, end user and ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
For primary and revision cases...
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Standard Erlanger hip stem....
Cemented foundation 460 series....
Medicine Products: